TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04557514

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: platelet rich plasma injection in post burn facial scar
Description: 2 spins\>\>\>~1. st spin (separate plasma from blood) 2500 for 10 minutes~2. nd spin (separate platelet rich part of plasma) 1500 for 10 minutes Taking lower part (platelet rich plasma ) Injection under scar after rigotomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: platelet rich plasma injection in post burn facial scar
Description: 2 spins\>\>\>~1. st spin (separate plasma from blood) 2500 for 10 minutes~2. nd spin (separate platelet rich part of plasma) 1500 for 10 minutes Taking lower part (platelet rich plasma ) Injection under scar after rigotomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fat injection in post burn facial scar
Description: Anesthesia : general or local Lipoaspirate from abdomen or thigh using adrenaline(1\\1000000) + ringer lactate + zylocaine Liposuction by canula no4 Sediment 3 layers : taking mid layer of fat and omit uppermost and lowermost layers Lipoinjection in fan shaped manner 10-20 cc according to site affected by canula no 1 .

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fat injection in post burn facial scar
Description: Anesthesia : general or local Lipoaspirate from abdomen or thigh using adrenaline(1\\1000000) + ringer lactate + zylocaine Liposuction by canula no4 Sediment 3 layers : taking mid layer of fat and omit uppermost and lowermost layers Lipoinjection in fan shaped manner 10-20 cc according to site affected by canula no 1 .
Study: NCT02471560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dimethyl fumarate
Description: As per the prevailing local label.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: injectable MS DMT
Description: As described above.
Study: NCT02324205

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DBT and FFDM
Description: Subjects underwent breast imaging using each device: DBT and FFDM.
Study: NCT02778555

Intervention type: BEHAVIORAL
Intervention: Questionnaires

Intervention type: BEHAVIORAL
Intervention: Questionnaires

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Study: NCT03585036

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexketoprofen
Description: Drug: dexketoprofen Women will receive oral dexketoprofen 25mg 2 hours before the procedure~Drug: Placebo 1 Women will receive an oral placebo similar to Tramadol 2 hours before the procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Drug: Tramadol Women will receive oral Tramadol 100 mg 2 hours before the procedure~Drug: Placebo 2 Women will receive an oral placebo similar to dexketoprofen 2 hours before the procedure

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug: Placebo 1 Women will receive an oral placebo similar to Tramadol 2 hours before the procedure.~Drug: Placebo 2 Women will receive an oral placebo similar to dexketoprofen 2 hours before the procedure
Study: NCT00531557

Intervention type: DRUG
Group type: OTHER
Intervention: Darunavir ritonavir
Study: NCT02382029

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonazepam
Description: Active medical treatment for burning mouth syndrome

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Traditional chinese acupuncture
Study: NCT03118427

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: zero-fluoroscopy 3D navigation
Description: Pacemaker implantation will be performed without fluoroscopy using 3D navigation systems.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional x-ray navigation
Description: Pacemaker implantation will be performed with fluoroscopy using conventional X-ray navigation.
Study: NCT01572363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: 50 mg once
Study: NCT02152371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Description: Administered SQ
Study: NCT01443754

Intervention type: PROCEDURE
Intervention: PCI
Description: State of the art drug eluting stent (DES)-based percutaneous coronary intervention will be used by each participating site, according to current international guidelines.~Zotarolimus, everolimus or sirolimus drug-eluting stents will be used in all sites.
Study: NCT01314443

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Description: Participants will quit smoking with nicotine patches

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Description: Participants will quit smoking with nicotine patches

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gamma-Tocopherol
Description: Participants will take gamma-tocopherol (500 mg/d) supplements for 7 days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gamma-Tocopherol
Description: Participants will take gamma-tocopherol (500 mg/d) supplements for 7 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will take placebo for 7 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will take placebo for 7 days

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking cessation
Description: Participants will quit smoking without any pharmacological aids

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking cessation
Description: Participants will quit smoking without any pharmacological aids
Study: NCT02299609

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Ultrasound beams Philips HD11 XE®
Description: Ultrasound beams used during standard echocardiography

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound beams Philips HD11 XE®
Description: Ultrasound beams used during standard echocardiography
Study: NCT02152371

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SQ

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: Administered SQ
Study: NCT03140020

Intervention type: PROCEDURE
Intervention: Clipping
Description: During the microsurgical operation a titan clip will be placed round the aneurysm neck to exclude the aneurysm from the bloodflow and prevent fatal subarachnoidal hemorrhage.

Intervention type: PROCEDURE
Intervention: Coiling
Description: Using a catheter technique the aneurysm dome will be filled up with coils to prevent subarachnoidal hemorrhage.
Study: NCT03465202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Study: NCT03041402

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PSP
Description: PSP, setting the inspiratory pressure support ≥8 cmH2O to obtain a tidal volume of 6-8 mL•kg-1 of body weight, the fastest rate of pressurization (0.0 sec) and I/E cycling at 35% of peak inspiratory flow

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PSP
Description: PSP, setting the inspiratory pressure support ≥8 cmH2O to obtain a tidal volume of 6-8 mL•kg-1 of body weight, the fastest rate of pressurization (0.0 sec) and I/E cycling at 35% of peak inspiratory flow
Study: NCT02152371

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin Glargine
Description: Administered SQ

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Administered orally
Study: NCT01028534

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olmesartan and Azelnidipine
Description: 1. Olmesartan 20mg per day for 3 months and, if hypertension is not controlled, increase Olmesartan to 40mg per day for the next 3 months~2. Olmesartan 20mg per day for 3 months and, if hypertension is not controlled, add Azelnidipine 16mg per day for the next 3 months~3. Azelnidipine 16mg per day for 3 months, and, if hypertension is not controlled, add Olmesartan 20mg per day for the next 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olmesartan and Azelnidipine
Description: 1. Olmesartan 20mg per day for 3 months and, if hypertension is not controlled, increase Olmesartan to 40mg per day for the next 3 months~2. Olmesartan 20mg per day for 3 months and, if hypertension is not controlled, add Azelnidipine 16mg per day for the next 3 months~3. Azelnidipine 16mg per day for 3 months, and, if hypertension is not controlled, add Olmesartan 20mg per day for the next 3 months
Study: NCT03041402

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PSP
Description: PSP, setting the inspiratory pressure support ≥8 cmH2O to obtain a tidal volume of 6-8 mL•kg-1 of body weight, the fastest rate of pressurization (0.0 sec) and I/E cycling at 35% of peak inspiratory flow

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NAVA
Description: NAVA, adjusting the NAVA level in order to achieve a comparable peak EAdi (EAdipeak) as during PSP with a safety Paw upper limit of 30 cmH2O

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NAVA
Description: NAVA, adjusting the NAVA level in order to achieve a comparable peak EAdi (EAdipeak) as during PSP with a safety Paw upper limit of 30 cmH2O

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NAVA
Description: NAVA, adjusting the NAVA level in order to achieve a comparable peak EAdi (EAdipeak) as during PSP with a safety Paw upper limit of 30 cmH2O

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PSN
Description: PSN, setting the NAVA level at its maximum (i.e; 15 cmH2O/mcV), and an upper Paw limit such to obtain the same overall Paw applied during PSP
Study: NCT01028534

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olmesartan and Azelnidipine
Description: 1. Olmesartan 20mg per day for 3 months and, if hypertension is not controlled, increase Olmesartan to 40mg per day for the next 3 months~2. Olmesartan 20mg per day for 3 months and, if hypertension is not controlled, add Azelnidipine 16mg per day for the next 3 months~3. Azelnidipine 16mg per day for 3 months, and, if hypertension is not controlled, add Olmesartan 20mg per day for the next 3 months
Study: NCT04676841

Intervention type: DEVICE
Intervention: Conventional ventilation + instrumental tables with integrated laminar airflow
Description: Surgical instruments protected from contamination by local laminar airflow

Intervention type: DEVICE
Intervention: Conventional ventilation + standard instrumental tables
Description: Control

Intervention type: DEVICE
Intervention: Laminar airflow ventilation + standard instrumental tables
Description: Control
Study: NCT01502878

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nut challenge
Description: Nut powder made from non-roasted nuts and roasted banana mixed with oats yoghurt or chocolate pudding

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nut challenge: Placebo
Description: Dried banana mixed with oat yoghurt or chocolate pudding

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nut oral desensitization
Description: Roasted peanut powder mixed with milk- and soy-free margarine
Study: NCT02725814

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 24% Sucrose Solution
Description: Two minutes prior to the start of a painful procedure neonates will receive 0.12ml of 24% sucrose solution, over a period of no more than 1 minute. A pacifier will be offered immediately following sucrose administration for non-nutritive sucking if the infant is able to hold the pacifier securely. The sucrose study dose is to be repeated as needed based on pain response and procedure duration.
Study: NCT03628144

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Impact® Advanced Recovery
Description: The intervention drink Impact® will be ingested every two weeks since usually chemotherapy is delivered concurrently with radiation therapy in 2 week cycles. For patients who are placed on weekly or every 4 weeks chemotherapy dosing schedules, the treatment and control supplements will still be given every two weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Boost® High Protein
Description: The control supplement drink Boost® will be ingested every two weeks since usually chemotherapy is delivered concurrently with radiation therapy in 2 week cycles. For patients who are placed on weekly or every 4 weeks chemotherapy dosing schedules, the treatment and control supplements will still be given every two weeks.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Standard of Care: Weekly radiation therapy as already planned for each participant, at Moffitt clinic visits.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Standard of Care: Weekly radiation therapy as already planned for each participant, at Moffitt clinic visits.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Standard of Care: Chemotherapy as already planned for each participant.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Standard of Care: Chemotherapy as already planned for each participant.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of life (EORTC-QLQ-30)
Description: Participants will undergo pre- and post-treatment assessments.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality of life (EORTC-QLQ-30)
Description: Participants will undergo pre- and post-treatment assessments.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation of Cognitive Function (FACT-Cog, v. 3.0)
Description: Participants will undergo pre- and post-treatment assessments.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation of Cognitive Function (FACT-Cog, v. 3.0)
Description: Participants will undergo pre- and post-treatment assessments.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness Questionnaire (FFMQ)
Description: Participants will undergo pre- and post-treatment assessments.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Questionnaire (FFMQ)
Description: Participants will undergo pre- and post-treatment assessments.
Study: NCT01310543

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teens and Toddlers
Description: The T\&T intervention aims to prevent teenage pregnancy and promote sexual health by providing young women at risk of teenage pregnancy with regular and direct contact with a toddler and combines this with 12 modules of group-based personal-development sessions involving communication skills, anger management, discussion of positive sexual health and relationships, culminating in an accredited National Award in Interpersonal Skills. One-to-one life coaching is also provided. The intervention consists of 20 weekly afternoon sessions run in nurseries near to the secondary schools from which participating young women are recruited.
Study: NCT02052336

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CJ-12420 200mg + Clarithromycin 500mg
Description: To assess the effect of the coadministration of multiple dose of CJ-12420 and clarithromycin on the pharmacokinetics (PK) of CJ-12420 or clarithromycin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CJ-12420 200mg + Clarithromycin 500mg
Description: To assess the effect of the coadministration of multiple dose of CJ-12420 and clarithromycin on the pharmacokinetics (PK) of CJ-12420 or clarithromycin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-12420 200mg
Description: To assess the effect of the coadministration of multiple dose of CJ-12420 and clarithromycin on the pharmacokinetics (PK) of CJ-12420 or clarithromycin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CJ-12420 200mg
Description: To assess the effect of the coadministration of multiple dose of CJ-12420 and clarithromycin on the pharmacokinetics (PK) of CJ-12420 or clarithromycin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500mg
Description: To assess the effect of the coadministration of multiple dose of CJ-12420 and clarithromycin on the pharmacokinetics (PK) of CJ-12420 or clarithromycin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin 500mg
Description: To assess the effect of the coadministration of multiple dose of CJ-12420 and clarithromycin on the pharmacokinetics (PK) of CJ-12420 or clarithromycin.
Study: NCT02260778

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Learning Collaborative
Description: A learning collaborative is an established technique that uses the model for improvement to bridge the gap between what we know and what we do. Structured learning sessions and collaborative coaching are used to guide small cycles of change called Plan-Do-Study-Act (PDSA) cycles. This quality improvement intervention will help providers adopt treat-to-target practices through the structured learning collaborative.
Study: NCT02154100

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tart Cherry
Description: 12 weeks of tart cherry juice taken in two doses of 240 ml per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 12 weeks of tart cherry juice taken in two doses of 240 ml per day.
Study: NCT02480491

Intervention type: OTHER
Intervention: measuring cell freeDNA
Description: measuring cell free DNA using PCR

Intervention type: OTHER
Intervention: measuring cell freeDNA
Description: measuring cell free DNA using PCR
Study: NCT01969383

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heated pool training
Study: NCT03420391

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Photobiomodulation Therapy (PBMT)
Description: Phototherapy device - Multi Radiance Medical® (Solon, OH, EUA)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Photobiomodulation Therapy (PBMT)
Description: Phototherapy device - Multi Radiance Medical® (Solon, OH, EUA)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Photobiomodulation Therapy (PBMT)
Description: Phototherapy device - Multi Radiance Medical® (Solon, OH, EUA)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Photobiomodulation Therapy (PBMT)
Description: Phototherapy device - Multi Radiance Medical® (Solon, OH, EUA)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Photobiomodulation Therapy (PBMT)
Description: Phototherapy device - Multi Radiance Medical® (Solon, OH, EUA)
Study: NCT03651856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATM FOG in PD
Description: open label pilot study on atomoxetine 40mg BID on patients with Parkinson's disease and Freezing of Gait
Study: NCT00856089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retapamulin
Description: Retapamulin ointment, 1%, apply a thin layer, BID for 5 days
Study: NCT05519436

Intervention type: OTHER
Intervention: Assessment
Description: Bioelectrical impedance analysis method was used to evaluate the body composition of the cases. Muscle, fat, water ratio was made with Inbody Bioelectrical Impedance Device. Static and dynamic plantar pressure analyzes were evaluated with Sensor Medica pedobarographic measuring device, and postural sway was evaluated with bilateral comparison tests, one of the dynamic balance tests of Biodex Balance System.

Intervention type: OTHER
Intervention: Assessment
Description: Bioelectrical impedance analysis method was used to evaluate the body composition of the cases. Muscle, fat, water ratio was made with Inbody Bioelectrical Impedance Device. Static and dynamic plantar pressure analyzes were evaluated with Sensor Medica pedobarographic measuring device, and postural sway was evaluated with bilateral comparison tests, one of the dynamic balance tests of Biodex Balance System.
Study: NCT02655523

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone
Description: 1 mL of 40 mg of Triamcinolone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 1 mL of 4mg of Dexamethasone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 1 mL of preservative free normal saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 2 mL of 0.5% bupivacaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine
Description: 2 mL of 0.5% bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 2 mL of 0.5% bupivacaine
Study: NCT02839577

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High Volume injection without corticosteroid
Description: Injection with 10 mls 0.5% bupivacaine hydrochloride and~• 40 ml saline around the tendon.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High Volume injection with corticosteroid
Description: Injection with 10 mls 0.5% bupivacaine hydrochloride, 20 mg Depomedrol and 40 ml saline around the tendon.
Study: NCT03041402

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PSN
Description: PSN, setting the NAVA level at its maximum (i.e; 15 cmH2O/mcV), and an upper Paw limit such to obtain the same overall Paw applied during PSP

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PSN
Description: PSN, setting the NAVA level at its maximum (i.e; 15 cmH2O/mcV), and an upper Paw limit such to obtain the same overall Paw applied during PSP
Study: NCT02408640

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cannabishjalpen.se
Study: NCT00451048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: Given orally
Study: NCT00856375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-102
Description: IV every 3 weeks
Study: NCT01349322

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard fractionation whole breast irradiation
Description: Target-based radiation using three-dimensional conformal radiation therapy (3D-CRT) or intensity-modulated radiation therapy (IMRT) to deliver 25 fractions of 2.0 Gy for a total dose of 50.0 Gy or 16 fractions of 2.67 Gy for a total dose of 42.7 Gy. Must begin within 9 weeks of last surgery or chemotherapy delivery.
Study: NCT00856375

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: irinotecan
Description: IV every 3 weeks
Study: NCT02174289

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Targeted left ventricular endocardial lead placement
Description: The left ventricular endocardial lead will be passed through the intra-atrial septum

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Targeted left ventricular endocardial lead placement
Description: The left ventricular endocardial lead will be passed through the intra-atrial septum
Study: NCT02493192

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pethidine and haloperidol injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: birth ball
Study: NCT01882972

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Meditation